Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $66.33 million. The enterprise value is -$129.74 million.
Important Dates
The last earnings date was Thursday, March 27, 2025, before market open.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 60.57 million shares outstanding. The number of shares has increased by 23.46% in one year.
| Current Share Class | 60.57M |
| Shares Outstanding | 60.57M |
| Shares Change (YoY) | +23.46% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 15.33% |
| Owned by Institutions (%) | 41.13% |
| Float | 32.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.46 |
| Quick Ratio | 6.24 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.03 |
Financial Efficiency
Return on equity (ROE) is -45.60% and return on invested capital (ROIC) is -27.97%.
| Return on Equity (ROE) | -45.60% |
| Return on Assets (ROA) | -25.95% |
| Return on Invested Capital (ROIC) | -27.97% |
| Return on Capital Employed (ROCE) | -53.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.97M |
| Employee Count | 52 |
| Asset Turnover | n/a |
| Inventory Turnover | 729.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.98% in the last 52 weeks. The beta is 0.02, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -70.98% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 2.22 |
| Relative Strength Index (RSI) | 41.93 |
| Average Volume (20 Days) | 195,978 |
Short Selling Information
The latest short interest is 1.78 million, so 2.93% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short Previous Month | 1.79M |
| Short % of Shares Out | 2.93% |
| Short % of Float | 5.41% |
| Short Ratio (days to cover) | 8.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | -93.80M |
| Operating Income | -114.02M |
| Pretax Income | -55.94M |
| Net Income | -102.33M |
| EBITDA | -113.95M |
| EBIT | -114.02M |
| Earnings Per Share (EPS) | -$1.71 |
Full Income StatementBalance Sheet
The company has $171.56 million in cash and $29.70 million in debt, giving a net cash position of $201.82 million or $3.33 per share.
| Cash & Cash Equivalents | 171.56M |
| Total Debt | 29.70M |
| Net Cash | 201.82M |
| Net Cash Per Share | $3.33 |
| Equity (Book Value) | 181.82M |
| Book Value Per Share | 3.03 |
| Working Capital | 150.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$86.22 million and capital expenditures -$16,000, giving a free cash flow of -$86.23 million.
| Operating Cash Flow | -86.22M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -86.23M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |